Using single maintenance and reliever therapy (SMART) is cost‐effective vs ICS/LABA maintenance plus SABA reliever in uncontrolled asthma.

Scientists at deCODE genetics have uncovered a rare genetic variant in the STAT6 gene that protects against asthma, a ...

USA: Recent findings published in The Journal of Allergy and Clinical Immunology highlight the potential for long-term ...

Discover a study that shows that modulating STAT6 directly may represent an innovative strategy for managing severe, ...

Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

A key driver in the market’s expansion is the segment addressing severe asthma with fungal sensitization (SAFS), which is ...

At the recent American College of Allergy, Asthma & Immunology (ACAAI) annual meeting, experts discussed the evolving concept ...

In even more severe cases, theophylline or roflumilast ... such as omalizumab, for the treatment of asthma. Broad-spectrum drugs may include bronchodilators, corticosteroids, theophylline and ...

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca ... Airsupra was found to significant reduce the risk of severe exacerbations compared to albuterol in patients with ...

To effectively manage chronic respiratory diseases like asthma and COPD, early intervention and strict adherence to doctor ...

A study published in JAMA reports on data showing that Combination ICS-SABA and ICS-Formoterol asthma treatments are more effective than SAMA-only treatment. Details of the study were presented in ...

Tezspire's 2021 approval in severe asthma represents a rapidly growing biologic market opportunity ... to deliver ...